Charcot-Marie-Tooth disease and related neuropathies

Area of Science:

• Neurology
• Genetics
• Molecular Biology

Background:

• Charcot-Marie-Tooth disease (CMT) encompasses diverse inherited neuropathies, affecting approximately 1 in 2,500 individuals globally.
• It represents a leading cause of inherited neurological disorders, impacting both males and females.
• CMT pathogenesis involves mutations affecting myelin proteins, cellular stress responses, endosomal pathways, transcription factors, mitochondrial function, aminoacyl-tRNA synthetases, molecular chaperones, or the axonal cytoskeleton.

Purpose of the Study:

• To provide a comprehensive overview of Charcot-Marie-Tooth disease (CMT), including its genetic basis, clinical manifestations, and current management strategies.
• To highlight the significant impact of CMT on patients' quality of life.
• To emphasize the urgent need for developing disease-modifying therapies and effective evaluation methods.

Main Methods:

• Review of genetic mutations associated with demyelinating and axonal forms of CMT.
• Analysis of clinical impairments resulting from progressive axonal loss.
• Examination of current management approaches, including rehabilitative, surgical, and symptomatic treatments.

Main Results:

• All CMT forms lead to length-dependent axonal loss, causing progressive weakness, deformities, and sensory deficits.
• Patients with CMT experience a reduced quality of life, particularly in physical domains.
• No disease-modifying therapies are currently available for any CMT type.

Conclusions:

• Effective management of CMT relies on rehabilitative strategies, surgical interventions, and symptom management.
• Development of genetically authentic models is crucial for advancing rational therapeutic strategies.
• Natural history studies and biomarkers are essential for rigorously evaluating future treatments for CMT.